AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. | AstraZeneca’s Imfinzi has proven it can help ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with gemcitabine and cisplatin chemotherapy as a neoadjuvant treatment before bladder ...

AstraZeneca received a positive recommendation from the European Medicines Agency for its cancer therapy Imfinzi, marking a significant advancement in its oncology portfolio. Despite this ...

AstraZeneca (NASDAQ:AZN) announced Tuesday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its anti-PD-L1 immunotherapy Imfinzi as part of a ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...